Marincola FM - Search Results

1

Kinetics of TCR use in response to repeated epitope-specific immunization.

Monsurrò V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM. Monsurrò V, et al. Among authors: marincola fm. J Immunol. 2001 May 1;166(9):5817-25. doi: 10.4049/jimmunol.166.9.5817. J Immunol. 2001. PMID: 11313426

2

Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.

Seiter S, Monsurro V, Nielsen MB, Wang E, Provenzano M, Wunderlich JR, Rosenberg SA, Marincola FM. Seiter S, et al. Among authors: marincola fm. J Immunother. 2002 May-Jun;25(3):252-63. doi: 10.1097/01.CJI.0000015209.05216.79. J Immunother. 2002. PMID: 12000867 Free PMC article.

3

Functional heterogeneity of vaccine-induced CD8(+) T cells.

Monsurrò V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM. Monsurrò V, et al. Among authors: marincola fm. J Immunol. 2002 Jun 1;168(11):5933-42. doi: 10.4049/jimmunol.168.11.5933. J Immunol. 2002. PMID: 12023400 Free PMC article.

4

Characterization of CD8(-) HLA class I/epitope tetrameric complexes binding T cells.

Nagorsen D, Monsurrò V, Wang E, Marincola FM. Nagorsen D, et al. Among authors: marincola fm. J Immunother. 2002 Sep-Oct;25(5):379-84. doi: 10.1097/00002371-200209000-00001. J Immunother. 2002. PMID: 12218775

5

Intensity of the vaccine-elicited immune response determines tumor clearance.

Perez-Diez A, Spiess PJ, Restifo NP, Matzinger P, Marincola FM. Perez-Diez A, et al. Among authors: marincola fm. J Immunol. 2002 Jan 1;168(1):338-47. doi: 10.4049/jimmunol.168.1.338. J Immunol. 2002. PMID: 11751979 Free PMC article.

6

Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.

Marincola FM, Ettinghausen S, Cohen PA, Cheshire LB, Restifo NP, Mulé JJ, Rosenberg SA. Marincola FM, et al. J Immunol. 1994 Apr 1;152(7):3500-13. J Immunol. 1994. PMID: 8144931 Free PMC article.

7

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Salgaller ML, et al. Among authors: marincola fm. Cancer Res. 1996 Oct 15;56(20):4749-57. Cancer Res. 1996. PMID: 8840994 Clinical Trial.

8

Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination.

Lee KH, Panelli MC, Kim CJ, Riker AI, Bettinotti MP, Roden MM, Fetsch P, Abati A, Rosenberg SA, Marincola FM. Lee KH, et al. Among authors: marincola fm. J Immunol. 1998 Oct 15;161(8):4183-94. J Immunol. 1998. PMID: 9780192

9

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White DE. Rosenberg SA, et al. Among authors: marincola fm. J Immunol. 1999 Aug 1;163(3):1690-5. J Immunol. 1999. PMID: 10415076 Free PMC article. Clinical Trial.

10

Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.

Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Lee KH, et al. Among authors: marincola fm. J Immunol. 1999 Dec 1;163(11):6292-300. J Immunol. 1999. PMID: 10570323 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

588 results

Search Page

Filters